Information Provided By: 
Fly News Breaks for April 20, 2015
AZN, CLVS
Apr 20, 2015 | 06:02 EDT
Mizuho analyst Peter Lawson sees a buying opportunity for shares of Clovis (CLVS) after the stock sold off Friday following AstraZeneca's (AZN) updated data for AZD9291. Lawson notes AZD9291 pulled ahead of Clovis's data "for the moment," with both datasets remaining "highly immature." He thinks Clovis remains well positioned and reiterates a Buy rating on the name with a $100 price target.
News For CLVS;AZN From the Last 2 Days
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
